THERAVANCE INC - CORPORATE OBLIG

CUSIP: 88338TAB0

Q2 2021 13F Holders as of 30 Jun 2021

Type / Class
Debt / CORPORATE OBLIG
Market price (% of par)
101.63%
Total 13F principal
$219,559,083
Principal change
-$14,957,500
Total reported market value
$223,823,303
Number of holders
26
Value change
-$14,403,472
Number of buys
14
Number of sells
7

Quarterly Holders Quick Answers

What is CUSIP 88338TAB0?
CUSIP 88338TAB0 identifies 88338TAB0 - THERAVANCE INC - CORPORATE OBLIG in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of THERAVANCE INC - CORPORATE OBLIG as of Q2 2021

As of 30 Jun 2021, THERAVANCE INC - CORPORATE OBLIG was held by 26 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $219,559,083 in principal (par value) of the bond. The largest 10 bondholders included LAZARD ASSET MANAGEMENT LLC, ADVENT CAPITAL MANAGEMENT /DE/, Radcliffe Capital Management, L.P., D. E. Shaw & Co., Inc., OAKTREE CAPITAL MANAGEMENT LP, Shaolin Capital Management LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, CNH PARTNERS LLC, DEUTSCHE BANK AG\, and NEW YORK STATE COMMON RETIREMENT FUND. This page lists 26 institutional bondholders reporting positions for the Q2 2021 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.